GTR 117169575
Tenders Are Invited For Blood-Testing Reagents – Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For Multiple Laboratories
ICB — International Competitive Bid
Closes Oct 12, 2026
Western Europe
Tender Information
GTR Reference
117169575
Tendering Authority
Subscribe to view
Tender No
576741-2026
Financer Name
Self-Funded
Work Title
Tenders Are Invited For Blood-Testing Reagents – Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For Multiple Laboratories
Bid Type
ICB — International Competitive Bid
Country
Subscribe to view
Geographical Region
Western Europe
Political Region
European Union
Last Date of Bid Submission
12-10-2026
Work Detail
Blood-Testing Reagents – Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For Multiple Laboratories. The Neonatal Heel Prick Screening (Nhs) Is A National Screening Program That Is Carried Out On Newborns In The First Week After Birth. In The Netherlands (European And Caribbean Netherlands), Approximately 170,000 Newborns Receive The Heel Prick Every Year. The Heel Prick Screening Is The Longest-Running National Screening Program In Public Health Care. The Analysis Of The Heel Prick Blood Currently Provides Important Information About Twenty-Seven Rare, Often Hereditary, Serious Conditions. From 2026, The Blood Test Will Be Carried Out By Three Screening Laboratories, Of Which The Rivm-Gzb Screening Laboratory Functions As A Reference Laboratory. The Screening Laboratories Are Responsible For The Analysis Of The Heel Prick Blood Sample And Timely Reporting Of The Results. From January 2021, All Screening Laboratories Will Use A Total Solution For Screening For Scid. From June 1, 2022, Sma Has Also Been Added To The Program And The Laboratories Will Screen With A Multiplex Total Solution That Can Screen For Both Scid And Sma. In Addition, It Is Possible That In The Coming Years It Will Be Decided That Screening For X-Linked Agammaglobulinemia (Xla) Should Be Performed. To Ensure Uniformity, Rivm Has Decided To Purchase The Equipment (Hardware), Software, Reagents And Associated Maintenance (Preventive, Corrective, Adaptive), Also Known As The Total Solution, And Make Them Available To The Screening Laboratories. This Tender Procedure Concerns An Order For The Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For The Screening Laboratories. The Purpose Of This European Tender Is To Conclude An Agreement With One Contractor, According To The Principle Of Reagent Rental, Whereby The Supplier Remains The Owner Of The Equipment. The Contractor Will Be Fully Responsible For Delivering, Implementing And Continuously Making Available The Total Solution And Providing Related Services In Accordance With The Specifications Laid Down In The Tender Documents.
Key Value
Tender Value
15,000,000 - EUR
Tender Documents
Global Tender Document
0fb95a24-2bf2-4cbd-b662-75a4be6d0135.html
Attachments
Additional Details Available on Click
- Tendering Authority
- Publication Document (Tender Document / Tender Notice)
Disclaimer
We take all possible care for accurate & authentic tender information. However, users are requested to refer to the original Tender Notice / Tender Document published by the Tender Issuing Agency before taking any decision regarding this tender.